Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (1,207 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Organs which might be damaged during exposure to a toxin or to some form of therapy. It most frequently refers to healthy organs located in the radiation field during radiation therapy.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: at Risk, Organs; at Risks, Organs; Organs at Risks; Risk, Organs at; Risks, Organs at.
Where it fits in the MeSH classification
- Broader topics
- Body Regions
- See also
- Risk Factors; Organ Sparing Treatments; Radiotherapy Setup Errors
Research landscape
PubMed indexes 6,629 records tagged with the MeSH heading “Organs at Risk” (counts retrieved 2026-10-31). 3,307 of them (49.9%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 3,404 records.
Reviews account for 554 records (8.4%) and meta-analyses for 27. Randomized controlled trials number 134 (2.0%) as a share of all records on the topic.
Show the data
| Period | Records |
|---|---|
| through 1999 | 0 |
| 2000-2009 | 7 |
| 2010-2019 | 3,404 |
| 2020 onward | 3,307 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 554 | 8.4% |
| Meta-analyses | 27 | 0.4% |
| Randomized controlled trials | 134 | 2.0% |
Method: PubMed query "Organs at Risk"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in anatomy and physiology
Anatomy describes how body structures are built and physiology describes how they normally work, so most findings here are descriptive or mechanistic rather than evidence about treatment. Much of what is known comes from dissection, imaging, tissue studies and experiments in animals, and measurements in healthy volunteers can differ from those in people with disease or at different ages. Normal ranges vary between individuals and populations. Check whether a result was measured in people or in another species, the age and health of the participants, and the method used.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Interobserver variability in organ at risk delineation in head and neck cancer | 2021 | Research article Design not recorded in structured metadata | 76 | cc by PMID 34183040 · DOI · PMC8240214 |
| Clinical feasibility of deep learning-based auto-segmentation of target volumes and organs-at-risk in breast cancer patients after breast-conserving surgery | 2021 | Research article Design not recorded in structured metadata | 54 | cc by PMID 33632248 · DOI · PMC7905884 |
| Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study | 2019 | Research article Design not recorded in structured metadata | 47 | cc by PMID 31822293 · DOI · PMC6905024 |
| Evaluation of AI-based auto-contouring tools in radiotherapy: A single-institution study | 2025 | Research article Design not recorded in structured metadata | 12 | cc by PMID 39837647 · DOI · PMC11969097 |
Interobserver variability in organ at risk delineation in head and neck cancer [1]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundIn radiotherapy inaccuracy in organ at risk (OAR) delineation can impact treatment plan optimisation and treatment plan evaluation.
- Closing excerpt
- However, this study highlights that guidelines alone do not suffice to eliminate IOV and that more effort needs to be done to accomplish further treatment standardisation, for example with artificial intelligence.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (296 words)
BackgroundIn radiotherapy inaccuracy in organ at risk (OAR) delineation can impact treatment plan optimisation and treatment plan evaluation. Brouwer et al. showed significant interobserver variability (IOV) in OAR delineation in head and neck cancer (HNC) and published international consensus guidelines (ICG) for OAR delineation in 2015. The aim of our study was to evaluate IOV in the presence of these guidelines.MethodsHNC radiation oncologists (RO) from each Belgian radiotherapy centre were invited to complete a survey and submit contours for 5 HNC cases. Reference contours (OARref) were obtained by a clinically validated artificial intelligence-tool trained using ICG. Dice similarity coefficients (DSC), mean surface distance (MSD) and 95% Hausdorff distances (HD95) were used for comparison.ResultsFourteen of twenty-two RO (64%) completed the survey and submitted delineations. Thirteen (93%) confirmed the use of delineation guidelines, of which six (43%) used the ICG. The OARs whose delineations agreed best with the OARref were mandible [median DSC 0.9, range (0.8-0.9); median MSD 1.1 mm, range (0.8-8.3), median HD95 3.4 mm, range (1.5-38.7)], brainstem [median DSC 0.9 (0.6-0.9); median MSD 1.5 mm (1.1-4.0), median HD95 4.0 mm (2.3-15.0)], submandibular glands [median DSC 0.8 (0.5-0.9); median MSD 1.2 mm (0.9-2.5), median HD95 3.1 mm (1.8-12.2)] and parotids [median DSC 0.9 (0.6-0.9); median MSD 1.9 mm (1.2-4.2), median HD95 5.1 mm (3.1-19.2)]. Oral cavity, cochleas, PCMs, supraglottic larynx and glottic area showed more variation. RO who used the consensus guidelines showed significantly less IOV (p = 0.008).ConclusionsAlthough ICG for delineation of OARs in HNC exist, they are only implemented by about half of RO participating in this study, which partly explains the delineation variability. However, this study highlights that guidelines alone do not suffice to eliminate IOV and that more effort needs to be done to accomplish further treatment standardisation, for example with artificial intelligence.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34183040 · DOI · PMC8240214
Clinical feasibility of deep learning-based auto-segmentation of target volumes and organs-at-risk in breast cancer patients after breast-conserving surgery [2]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundIn breast cancer patients receiving radiotherapy (RT), accurate target delineation and reduction of radiation doses to the nearby normal organs is important.
- Closing excerpt
- Trial registration Retrospectively registered.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (300 words)
BackgroundIn breast cancer patients receiving radiotherapy (RT), accurate target delineation and reduction of radiation doses to the nearby normal organs is important. However, manual clinical target volume (CTV) and organs-at-risk (OARs) segmentation for treatment planning increases physicians' workload and inter-physician variability considerably. In this study, we evaluated the potential benefits of deep learning-based auto-segmented contours by comparing them to manually delineated contours for breast cancer patients.MethodsCTVs for bilateral breasts, regional lymph nodes, and OARs (including the heart, lungs, esophagus, spinal cord, and thyroid) were manually delineated on planning computed tomography scans of 111 breast cancer patients who received breast-conserving surgery. Subsequently, a two-stage convolutional neural network algorithm was used. Quantitative metrics, including the Dice similarity coefficient (DSC) and 95% Hausdorff distance, and qualitative scoring by two panels from 10 institutions were used for analysis. Inter-observer variability and delineation time were assessed; furthermore, dose-volume histograms and dosimetric parameters were also analyzed using another set of patient data.ResultsThe correlation between the auto-segmented and manual contours was acceptable for OARs, with a mean DSC higher than 0.80 for all OARs. In addition, the CTVs showed favorable results, with mean DSCs higher than 0.70 for all breast and regional lymph node CTVs. Furthermore, qualitative subjective scoring showed that the results were acceptable for all CTVs and OARs, with a median score of at least 8 (possible range: 0-10) for (1) the differences between manual and auto-segmented contours and (2) the extent to which auto-segmentation would assist physicians in clinical practice. The differences in dosimetric parameters between the auto-segmented and manual contours were minimal.ConclusionsThe feasibility of deep learning-based auto-segmentation in breast RT planning was demonstrated. Although deep learning-based auto-segmentation cannot be a substitute for radiation oncologists, it is a useful tool with excellent potential in assisting radiation oncologists in the future. Trial registration Retrospectively registered.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 33632248 · DOI · PMC7905884
Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundThe addition of regional nodal radiation (RNI) to whole breast irradiation for high risk breast cancer improves metastases free survival and new data suggests it contributes additional benefit to overall survival.
- Closing excerpt
- ConclusionsDIBH is a promising approach for right-breast radiotherapy with considerable sparing of normal tissue, particularly when the ipsilateral IMNs are also irradiated.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (322 words)
BackgroundThe addition of regional nodal radiation (RNI) to whole breast irradiation for high risk breast cancer improves metastases free survival and new data suggests it contributes additional benefit to overall survival. Deep inspiration breath hold (DIBH) has been shown to reduce cardiac and pulmonary dose in the context of left-sided disease treated with or without RNI, yet few studies have investigated its utility for right-breast cancer. This study investigates the potential advantages of DIBH in local and locoregional radiotherapy for right-sided breast cancer.MethodsFree-breathing (FB) and DIBH computed tomography datasets were obtained from twenty patients who previously underwent radiotherapy for left-sided breast cancer. Ten patients were retrospectively planned for whole right breast only irradiation and ten patients were planned for irradiation to the whole breast plus ipsilateral supra-clavicular (SC) nodes, with and without irradiation of the ipsilateral internal mammary nodes (IMN). Dose-volume metrics for the clinical target volume, lungs, heart, left anterior descending artery, right coronary artery (RCA) and liver were recorded. Differences between FB and DIBH plans were analysed using Wilcoxon signed-rank tests, with P ResultsDIBH increased the average total lung volume compared to FB in both breast only and breast plus RNI cohorts (P = 0.001). For the breast only group, there was no significant improvement in any ipsilateral lung dose-volume metric between FB and DIBH. However, for the breast plus RNI group, there was an improvement in ipsilateral lung mean dose (18.9 ± 3.2 Gy to 15.9 ± 2.3 Gy, P = 0.002) and V20Gy (45.3 ± 13.3% to 32.9 ± 9.4%, P = 0.002). In addition, DIBH significantly reduced the maximum dose to the RCA for RNI (11.6 ± 7.2 Gy to 5.6 ± 2.9 Gy, P = 0.03). Significant reductions in the liver V20Gy and maximum dose were observed in all cohorts during DIBH compared to FB.ConclusionsDIBH is a promising approach for right-breast radiotherapy with considerable sparing of normal tissue, particularly when the ipsilateral IMNs are also irradiated.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31822293 · DOI · PMC6905024
Evaluation of AI-based auto-contouring tools in radiotherapy: A single-institution study [4]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundAccurate delineation of organs at risk (OARs) is crucial yet time-consuming in the radiotherapy treatment planning workflow.
- Closing excerpt
- However, further refinement is necessary for several challenging OARs to improve model performance.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (289 words)
BackgroundAccurate delineation of organs at risk (OARs) is crucial yet time-consuming in the radiotherapy treatment planning workflow. Modern artificial intelligence (AI) technologies had made automation of OAR contouring feasible. This report details a single institution's experience in evaluating two commercial auto-contouring software tools and making well-informed decisions about their clinical adoption.MethodsA cohort of 36 patients previously treated at our institution were selected for the software performance assessment. Fifty-eight OAR structures from seven disease sites were automatically segmented with each tool. Five radiation oncologists with different specialties qualitatively scored the automatic OAR contours' clinical usability by a 4-level scale (0-3), termed as quality score (QS), representing from "0: not usable" to "3: directly usable for a clinic." Additionally, quantitative comparison with clinically approved contours using Dice similarity coefficient (DSC) and the 95% Hausdorff distance (HD95) was performed in complement to QS from physicians.ResultSoftware A achieved an average QS of 2.17 ± 0.69, comparable to Software B's average QS of 2.17 ± 0.72. Software B performed better with more OARs (42 vs. 37) that required minor or no modification than Software A. Major modifications were needed for 13 out of 58 automated contours from both tools. Both DSC and HD95 scores for the two tools were comparable to each other, with DSC: 0.67 ± 0.23 versus 0.66 ± 0.21 and HD95: 13.07 ± 15.84 versus 15.55 ± 18.45 for Software A and Software B, respectively. Correlation coefficients between the physician score and the quantitative metrics suggested that the contouring results from Software A aligned more closely with the physician's evaluations.ConclusionBased on our study, either software tool could produce clinically acceptable contours for about 65% of the OAR structures. However, further refinement is necessary for several challenging OARs to improve model performance.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39837647 · DOI · PMC11969097
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines [5]
- Research article Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas [6]
- Research article Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain [7]
- Research article Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship [8]
- Research article Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer [9]
- Research article Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group [10]
References
- van der Veen J, Gulyban A, Willems S, Maes F, Nuyts S. Interobserver variability in organ at risk delineation in head and neck cancer. . 2021. PMID 34183040 · DOI · PMC8240214
- Chung SY, Chang JS, Choi MS, Chang Y, Choi BS, Chun J, et al.. Clinical feasibility of deep learning-based auto-segmentation of target volumes and organs-at-risk in breast cancer patients after breast-conserving surgery. . 2021. PMID 33632248 · DOI · PMC7905884
- Pandeli C, Smyth LML, David S, See AW. Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study. . 2019. PMID 31822293 · DOI · PMC6905024
- Wang T, Tam J, Chum T, Tai C, Marshall DC, Buckstein M, et al.. Evaluation of AI-based auto-contouring tools in radiotherapy: A single-institution study. . 2025. PMID 39837647 · DOI · PMC11969097
- Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, et al.. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol. 2015. PMID 26277855 · DOI
- Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, et al.. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012. PMID 22483697 · DOI · PMC3904368
- Milano MT, Grimm J, Niemierko A, Soltys SG, Moiseenko V, Redmond KJ, et al.. Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain. Int J Radiat Oncol Biol Phys. 2021. PMID 32921513 · DOI · PMC9387178
- Berrington de Gonzalez A, Gilbert E, Curtis R, Inskip P, Kleinerman R, Morton L, et al.. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys. 2013. PMID 23102695 · DOI · PMC3816386
- Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al.. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012. PMID 22401917 · DOI
- Nielsen MH, Berg M, Pedersen AN, Andersen K, Glavicic V, Jakobsen EH, et al.. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. Acta Oncol. 2013. PMID 23421926 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.